Biomarkers associated with periimplant diseases

Implant Dentistry

Volumn 23, Issue 5, 2014, Pages 607-611

  Li, Jeff Yuanjun ^a   Wang, Hom Lay ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

Author keywords

Interleukin; Matrix metalloproteinase; Peri implantitis

Indexed keywords

BIOLOGICAL MARKER;

HUMAN; METABOLISM; PERIIMPLANTITIS;

BIOMARKERS; HUMANS; PERI-IMPLANTITIS;

EID: 84927647007     PISSN: 10566163     EISSN: None     Source Type: Journal    
DOI: 10.1097/ID.0000000000000129     Document Type: Article

References (39)

1. Lang NP, Pjetursson BE, Tan K, et al. A systematic review of the survival and complication rates of fixed partial dentures (FPDs) after an observation period of at least 5 years. II. Combined tooth-implant-supported FPDs. Clin Oral Implants Res. 2004;15:643-653.
2. Jung RE, Pjetursson BE, Glauser R, et al. A systematic review of the 5-year survival and complication rates of implant-supported single crowns. Clin Oral Implants Res. 2008;19:119-130.
3. Meffert RM, Langer B, Fritz ME. Dental implants: A review. J Periodontol. 1992;63:859-870.
4. Peri-implant mucositis and periimplantitis: A current understanding of their diagnoses and clinical implications. J Periodontol. 2013;84:436-443.
5. Lang NP, Berglundh T; Working Group 4 of Seventh European Workshop on Periodontology. Periimplant diseases: Where are we now?dConsensus of the Seventh European Workshop on Periodontology. J Clin Periodontol. 2011;38 (suppl)11:178-181.
6. Roos-Jansaker AM, Lindahl C, Renvert H, et al. Nine- to fourteen-year follow-up of implant treatment. Part II: Presence of peri-implant lesions. J Clin Periodontol. 2006;33:290-295.
7. Marrone A, Lasserre J, Bercy P, et al. Prevalence and risk factors for periimplant disease in Belgian adults. Clin Oral Implants Res. 2013;24:934-940.
8. Koldsland OC, Scheie AA, Aass AM. Prevalence of peri-implantitis related to severity of the disease with different degrees of bone loss. J Periodontol. 2010;81:231-238.
9. Panagakos FS, Aboyoussef H, Dondero R, et al. Detection and measurement of inflammatory cytokines in implant crevicular fluid: A pilot study. Int J Oral Maxillofac Implants. 1996;11:794-799.
10. Liskmann S, Vihalemm T, Salum O, et al. Correlations between clinical parameters and interleukin-6 and interleukin-10 levels in saliva from totally edentulous patients with peri-implant disease. Int J Oral Maxillofac Implants. 2006; 21:543-550.
11. Pietruski JK, Pietruska MD, Stokowska W, et al. Serum levels of interleukin-1 (IL-1), interleukin-6 (IL-6) and interleukin-8 (IL-8) in patients treated with dental implants. Rocz Akad Med Bialymst. 2001;46:28-37.
12. Nowzari H, Botero JE, DeGiacomo M, et al. Microbiology and cytokine levels around healthy dental implants and teeth. Clin Implant Dent Relat Res. 2008;10:166-173.
13. Salcetti JM, Moriarty JD, Cooper LF, et al. The clinical, microbial, and host response characteristics of the failing implant. Int J Oral Maxillofac Implants. 1997;12:32-42.
14. Konttinen YT, Lappalainen R, Laine P, et al. Immunohistochemical evaluation of inflammatory mediators in failing implants. Int J Periodontics Restorative Dent. 2006;26:135-141.
15. Bordin S, Flemmig TF, Verardi S. Role of fibroblast populations in periimplantitis. Int J Oral Maxillofac Implants. 2009;24:197-204.
16. Petkovic AB, Matic SM, Stamatovic NV, et al. Proinflammatory cytokines (IL-1beta and TNF-alpha) and chemokines (IL-8 and MIP-1alpha) as markers of peri-implant tissue condition. Int J Oral Maxillofac Surg. 2010;39:478-485.
17. Mengel R, Stelzel M, Hasse C, et al. Osseointegrated implants in patients treated for generalized severe adult periodontitis. An interim report. J Periodontol. 1996;67:782-787.
18. Duarte PM, de Mendonca AC, Maximo MB, et al. Differential cytokine expressions affect the severity of peri-implant disease. Clin Oral Implants Res. 2009;20: 514-520.
19. Duarte PM, de Mendonca AC, Maximo MB, et al. Effect of anti-infective mechanical therapy on clinical parameters and cytokine levels in human peri-implant diseases. J Periodontol. 2009;80:234-243.
20. Candel-Marti ME, Flichy-Fernandez AJ, Alegre-Domingo T, et al. Interleukins IL-6, IL-8, IL-10, IL-12 and periimplant disease. An update. Med Oral Patol Oral Cir Bucal. 2011;16: e518-521.
21. Murata M, Tatsumi J, Kato Y, et al. Osteocalcin, deoxypyridinoline and interleukin-1beta in peri-implant crevicular fluid of patients with periimplantitis. Clin Oral Implants Res. 2002; 13:637-643.
22. Ataoglu H, Alptekin NO, Haliloglu S, et al. Interleukin-1beta, tumor necrosis factor-alpha levels and neutrophil elastase activity in peri-implant crevicular fluid. Clin Oral Implants Res. 2002;13: 470-476.
23. Nomura T, Ishii A, Shimizu H, et al. Tissue inhibitor of metalloproteinases-1, matrix metalloproteinases-1 and -8, and collagenase activity levels in peri-implant crevicular fluid after implantation. Clin Oral Implants Res. 2000;11:430-440.
24. Arakawa H, Uehara J, Hara ES, et al. Matrix metalloproteinase-8 is the major potential collagenase in active periimplantitis. J Prosthodont Res. 2012;56: 249-255.
25. Basegmez C, Yalcin S, Yalcin F, et al. Evaluation of periimplant crevicular fluid prostaglandin E2 and matrix metalloproteinase-8 levels from health to periimplant disease status: A prospective study. Implant Dent. 2012;21:306-310.
26. Borsani E, Salgarello S, Mensi M, et al. Histochemical and immunohistochemical evaluation of gingival collagen and metalloproteinases in peri-implantitis. Acta Histochem. 2005;107:231-240.
27. Schierano G, Bellone G, Cassarino E, et al. Transforming growth factor-beta and interleukin 10 in oral implant sites in humans. J Dent Res. 2003;82:428-432.
28. Campos MI, Godoy dos Santos MC, Trevilatto PC, et al. Interleukin-2 and interleukin-6 gene promoter polymorphisms, and early failure of dental implants. Implant Dent. 2005;14:391-396.
29. Kao RT, Curtis DA, Richards DW, et al. Increased interleukin-1 beta in the crevicular fluid of diseased implants. Int J Oral Maxillofac Implants. 1995;10:696-701.
30. Klinge B, Gustafsson A, Berglundh T. A systematic review of the effect of antiinfective therapy in the treatment of periimplantitis. J Clin Periodontol. 2002;29 (suppl 3):213-225; discussion 232-213.
31. Quirynen M, De Soete M, van Steenberghe D. Infectious risks for oral implants: A review of the literature. Clin Oral Implants Res. 2002;13:1-19.
32. Chapple IL, Garner I, Saxby MS, et al. Prediction and diagnosis of attachment loss by enhanced chemiluminescent assay of crevicular fluid alkaline phosphatase levels. J Clin Periodontol. 1999;26: 190-198.
33. Gualini F, Berglundh T. Immunohistochemical characteristics of inflammatory lesions at implants. J Clin Periodontol. 2003;30:14-18.
34. Plagnat D, Giannopoulou C, Carrel A, et al. Elastase, alpha2-macroglobulin and alkaline phosphatase in crevicular fluid from implants with and without periimplantitis. Clin Oral Implants Res. 2002;13:227-233.
35. Aboyoussef H, Carter C, Jandinski JJ, et al. Detection of prostaglandin E2 and matrix metalloproteinases in implant crevicular fluid. Int J Oral Maxillofac Implants. 1998;13:689-696.
36. Yamalik N, Gunday S, Uysal S, et al. Analysis of cathepsin-K activity at tooth and dental implant sites and the potential of this enzyme in reflecting alveolar bone loss. J Periodontol. 2012;83: 498-505.
37. Arikan F, Buduneli N, Kutukculer N. Osteoprotegerin levels in peri-implant crevicular fluid. Clin Oral Implants Res. 2008;19:283-288.
38. Arikan F, Buduneli N, Lappin DF. C-telopeptide pyridinoline crosslinks of type I collagen, soluble RANKL, and osteoprotegerin levels in crevicular fluid of dental implants with peri-implantitis: A case-control study. Int J Oral Maxillofac Implants. 2011;26:282-289.
39. Rakic M, Lekovic V, Nikolic-Jakoba N, et al. Bone loss biomarkers associated with peri-implantitis. A cross-sectional study. Clin Oral Implants Res. 2013;24: 1110-1116.